Latest

25
Feb
The Boutique Consultancy Mirage

The Boutique Consultancy Mirage

Few phrases carry as much self-importance and ambiguity as “boutique consultancy”. It appears on websites, LinkedIn bios, and PowerPoint decks
3 min read
24
Feb
The Conference Conundrum: Pay-to-Play, Ego Panels, and Networking Woes

The Conference Conundrum: Pay-to-Play, Ego Panels, and Networking Woes

Let’s talk about a topic that doesn’t get enough attention but is painfully familiar to anyone in the
3 min read
23
Feb
The problem with LOA

The problem with LOA

Likelihood of Approval (LOA) is a widely referenced metric in drug development, particularly in the later stages of the pipeline.
4 min read
22
Feb
The problem with PTRS

The problem with PTRS

Probability of Technical and Regulatory Success (PTRS) is a widely used metric in biotech and pharma, employed to estimate the
4 min read
21
Feb
Assessing the Robustness of Biotech Valuations Using Fat-Tailed Models

Assessing the Robustness of Biotech Valuations Using Fat-Tailed Models

Biotech valuations, characterized by their high volatility and dependency on uncertain outcomes, present unique challenges to traditional financial modeling. The
4 min read
20
Feb
The Project Management Paradox: Why Big Pharma Execs Struggle in the Real World

The Project Management Paradox: Why Big Pharma Execs Struggle in the Real World

Project management—the noble art of being handed a budget, a timeline, and a goal, then tasked with delivering results
3 min read
19
Feb
Why Incorporating Fat Tails, Black Swans, and Extreme Value Theory (EVT) Can Improve Pitch Decks

Why Incorporating Fat Tails, Black Swans, and Extreme Value Theory (EVT) Can Improve Pitch Decks

Fat Tails, Black Swans, and Extreme Value Theory (EVT) offer a robust analytical framework for understanding rare, high-impact events that
5 min read
18
Feb
WhatsApp: From Skeptic to Believer—How It’s Building Communities

WhatsApp: From Skeptic to Believer—How It’s Building Communities

When I first considered WhatsApp as a professional communication channel, I was deeply skeptical. It felt too informal, too personal.
2 min read
17
Feb
The problem with POL

The problem with POL

Probability of Launch (POL) is a comprehensive metric designed to estimate the likelihood that a drug successfully completes all clinical
4 min read
16
Feb
The problem with DCF

The problem with DCF

1. Introduction: The Biotech Valuation Maze Biotech valuation is fraught with complexities that standard financial tools like Discounted Cash Flow
6 min read